Care and concern with cannabinoids used therapeutically.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Parasitic pharmacology: A plausible mechanism of action for cannabidiol.British journal of clinical pharmacology · 2020
   Article
2. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.British journal of clinical pharmacology · 2020
   Article
3. Cannabinoid use in practice in Australasia-Better guidance and new drug information systems will be essential for prescribers.British journal of clinical pharmacology · 2019
   Article
4. Care and concern with cannabinoids used therapeutically.British journal of clinical pharmacology · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as